0.4914

3.73% 0.0109

Pasithea Therapeutics Corp (KTTA)

Overview News Price History Financials Discussions Forecast

Pasithea Therapeutics Corp stock is traded at $0.4914, with a volume of 152.85K. It is up +3.73% in the last 24 hours and up +10.76% over the past month. Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Previous Close:

$0.4805

Open:

$0.487

24h Volume:

152.85K

Relative Volume:

0.21

Market Cap:

$16.42M

Revenue:

Net Income/Loss:

$-19.73M

P/E Ratio:

-0.2369

EPS:

-2.0742

Net Cash Flow:

$-16.94M

1W Performance:

+5.15%

1M Performance:

+10.76%

6M Performance:

-28.05%

1Y Performance:

-29.07%

1-Day Range:

$0.44

$0.5123

1-Week Range:

$0.44

$0.5123

52-Week Range:

$0.281

$2.06

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name

Pasithea Therapeutics Corp

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(702) 514-4174

Address

1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

KTTA's Discussions on Twitter

Compare KTTA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KTTA Pasithea Therapeutics Corp	0.4914	16.06M	0	-19.73M	-16.94M	-2.0742
VRTX Vertex Pharmaceuticals Inc	516.25	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.82	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.77	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.15	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.23	39.31B	5.76B	514.49M	1.10B	4.4813

Pasithea Therapeutics Corp Stock (KTTA) Latest News

Aug 14, 2026

Pasithea Therapeutics Company Profile & Introduction - Moomoo

Aug 14, 2026

Pasithea Therapeutics Corp reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary - TradingView

Aug 14, 2026

KTTA: Q2 2026 net loss rose to $5.27M as R&D spending surged; cash reserves at $45.7M - TradingView

Aug 14, 2026

Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock - Stock Titan

Aug 14, 2026

Aug 11, 2026

Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView

Aug 11, 2026

Aug 10, 2026

Pasithea Therapeutics Corp expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 07, 2026

Pasithea Therapeutics Corp. SEC Filing (Aug 7, 2026) - Stock Titan

Aug 07, 2026

Aug 01, 2026

Pasithea Therapeutics (KTTA) Edges Higher: Micro-Cap Biotech Approaches Key Resistance at $0.48Corrective Wave - dars.gov.et

Aug 01, 2026

Jul 31, 2026

Opaleye group (NASDAQ: KTTA) discloses 6.14% Pasithea Therapeutics ownership in 13G/A - stocktitan.net

Jul 31, 2026

Jul 29, 2026

Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote - Stock Titan

Jul 29, 2026

Jul 28, 2026